Combination Vaccination Before HIV Treatment Interruption
A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Volunteers will be randomly assigned to receive the vaccines or matching placebos before interrupting their antiretroviral therapy at week 24.
Dosage:
Remune(TM) 1 ml i.m.* at weeks 0, 12, and 20; ALVAC 1 ml i.m.* at weeks 8,12, 16, and 20.
* i.m.: injected in a muscle
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital, General Campus
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2P4
- Montreal Chest Institute
-
Montreal, Quebec, Canada, H2W 1T8
- CHUM Hôtel-Dieu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented HIV infection (by serology)
- HIV RNA level below 50 copies/ml for at least two years
- Receiving at least 2 antiretroviral agents including at least 1 protease inhibitor or 1 non-nucleoside reverse transcriptase inhibitor at time of screening
- Have CD4 counts above 500 cells/ul
- Have CD4/CD8 ratio above 0.5
- Have never had a CD4 count below 250
- No previous AIDS-defining opportunistic infection
- No previous cancer chemotherapy or other system immunosuppressive therapy (excluding brief courses [<= 1 month] of prednisone or its equivalent)
- Able to provide informed consent
Exclusion Criteria:
- Hepatitis B surface antigen positive
- Hepatitis C antibody positive
- AST, ALT, ALP, creatinine, urea above three times the normal upper limit
- Blood abnormalities (hemoglobin lower than 100, white blood cell count [WBC] lower than 1500 or platelets lower than 100)
- Allergies to components of Remune™ or ALVAC
- Contraindications to vaccine components
- Pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group
Time Frame: Up to week 48
|
Up to week 48
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Detectable Virus in the ALVAC Alone Group and the Placebo Group
Time Frame: Up to week 48
|
Up to week 48
|
|
|
Time to Rebound of Plasma HIV RNA Level to 10,000 Copies/ml
Time Frame: Up to week 48
|
Up to week 48
|
|
|
Viral Set-point
Time Frame: Up to week 48
|
Viral set-point is the viral load (HIV RNA) that the body settles at within a few weeks to months after infection with HIV.
|
Up to week 48
|
|
Magnitude of Viral Rebound
Time Frame: Up to week 48
|
Magnitude of viral rebound is the amount of HIV viral load an infected person who was previously on ART and suppressed below clinical detection rebounds to following ART stoppage.
This will typically be compared to the viral load before starting ART or Viral set-point discussed earlier.
|
Up to week 48
|
|
HIV-specific Immune Function
Time Frame: at week 48
|
at week 48
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jonathan B Angel, MD, OHRI
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2000456-01H
- CTA file 9427-C1574-32C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.